Washington Patent of the Month – April 2024
Corneal disorders affecting the endothelial cells can severely impair vision and overall eye health. To address such conditions, innovative approaches are constantly sought after in the field of ophthalmology. CorneaGen, Inc. has been granted a patent for a new approach to corneal tissue manipulation that promises to revolutionize treatments for endothelial cell disorders.
At the heart of this invention lies a sophisticated tissue manipulation device, meticulously designed to handle delicate corneal implants with precision. The method begins with the operation of a first actuator, engaging forceps located at the end of a guide extending from the device’s handle. These forceps delicately grasp the corneal implant, positioning it precisely at the target site within the eye’s posterior cornea.
But here’s where CorneaGen’s innovation truly shines: the second actuator comes into play, delivering air to the corneal implant from an air chamber nestled within the handle. This air, carefully channeled through the device, serves a crucial purpose in preparing the implant for optimal integration. By delivering a controlled volume of air to the implant, the device ensures that it assumes the necessary shape and orientation for successful placement.
The device’s design incorporates thoughtful features to enhance its functionality. Forceps equipped with a first and second jaw facilitate secure implant engagement, ensuring stability throughout the procedure. Additionally, a compressible air chamber, cleverly fashioned from pliable material, enables precise delivery of air to the implant site.
CorneaGen’s method isn’t just about delivering air—it’s about delivering the right amount, at the right time. With the capacity to deliver a specific volume of air, ranging from 0.25 cm3 to 0.50 cm3, the device ensures optimal conditions for implantation.
But the innovation doesn’t end there. CorneaGen’s device is designed for versatility, with features like dual-purpose structures and integrated lumen for fluid delivery, expanding its utility across various procedures and patient needs.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
